- Home
- RGC vs EARN Comparison
RGC vs EARN Comparison
Compare RGC & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- EARN
- Stock Information
- Founded
- RGC 2014
- EARN 2012
- Country
- RGC Hong Kong
- EARN United States
- Employees
- RGC N/A
- EARN N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- EARN Real Estate Investment Trusts
- Sector
- RGC Health Care
- EARN Real Estate
- Exchange
- RGC Nasdaq
- EARN Nasdaq
- Market Cap
- RGC 38.6B
- EARN 213.3M
- IPO Year
- RGC 2021
- EARN 2013
- Fundamental
- Price
- RGC $14.66
- EARN $5.92
- Analyst Decision
- RGC
- EARN Buy
- Analyst Count
- RGC 0
- EARN 2
- Target Price
- RGC N/A
- EARN $6.00
- AVG Volume (30 Days)
- RGC 2.8M
- EARN 230.9K
- Earning Date
- RGC 06-30-2025
- EARN 08-11-2025
- Dividend Yield
- RGC N/A
- EARN 16.16%
- EPS Growth
- RGC N/A
- EARN N/A
- EPS
- RGC N/A
- EARN N/A
- Revenue
- RGC N/A
- EARN $35,893,000.00
- Revenue This Year
- RGC N/A
- EARN $3.21
- Revenue Next Year
- RGC N/A
- EARN $18.63
- P/E Ratio
- RGC N/A
- EARN N/A
- Revenue Growth
- RGC N/A
- EARN 43.30
- 52 Week Low
- RGC $0.08
- EARN $4.33
- 52 Week High
- RGC $83.60
- EARN $7.20
- Technical
- Relative Strength Index (RSI)
- RGC 45.32
- EARN 64.84
- Support Level
- RGC $9.39
- EARN $5.71
- Resistance Level
- RGC $30.00
- EARN $5.79
- Average True Range (ATR)
- RGC 6.44
- EARN 0.06
- MACD
- RGC -1.70
- EARN 0.01
- Stochastic Oscillator
- RGC 20.68
- EARN 82.14
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.